Micell reduces size of DES trial following positive results
This article was originally published in Clinica
Executive Summary
Micell Technologies is to shrink its planned Phase II study of its MiStent drug-eluting stent (DES) following positive data from its first-in-human trial. The move could potentially accelerate the device's route to the European market.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.